Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2004-10-11
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 440
- Registration Number
- NCT00094016
- Locations
- 🇺🇸
NorthEast Medical Research Associates, North Dartmouth, Massachusetts, United States
🇺🇸The Asthma and Allergy Center, Papillion, Nebraska, United States
🇺🇸Allergy, Asthma & Dermatology Research Center, Lake Oswego, Oregon, United States
Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma
Phase 3
Completed
- Conditions
- Exercise-induced Bronchospasm
- Interventions
- First Posted Date
- 2004-06-17
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00085774
- Locations
- 🇺🇸
Colorado Allergy and Asthma Centers, PC, Lakewood, Colorado, United States
Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients
- First Posted Date
- 2003-10-29
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00071552
- Locations
- 🇺🇸
National Jewish Medical and Research Center, Denver, Colorado, United States
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Phase 2
Completed
- Conditions
- Recurrent Glioblastoma Multiforme
- Interventions
- Drug: TP-38Drug: TP38
- First Posted Date
- 2003-10-29
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00071539
Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
Phase 2
Terminated
- Conditions
- Glioblastoma MultiformeAnaplastic AstrocytomaAnaplastic OligodendrogliomaAnaplastic Mixed Oligoastrocytoma
- Interventions
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00062504
Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique
- First Posted Date
- 2003-02-17
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT00054964
- Locations
- 🇺🇸
National Jewish Medical and Research Ceter, Denver, Colorado, United States
Effects of Talampanel on Patients With Advanced Parkinson's Disease
Phase 1
Completed
- Conditions
- DyskinesiasParkinson DiseaseMovement Disorders
- Interventions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT00036296
Multicenter Trial For Patients With Acute Crohn's Disease
Phase 2
Completed
- Conditions
- Crohn's Disease
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT00035503
- Locations
- 🇺🇸
Richard MacDermott, Albany, New York, United States
🇺🇸University of Chicago Hospital Medical Center, Chicago, Illinois, United States
🇺🇸Stuart Weisman, Palo Alto, California, United States
Multicenter Trial for Adults With Partial Seizures
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2011-03-17
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT00034814
© Copyright 2025. All Rights Reserved by MedPath